217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Naoto T. Ueno, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Y.H. Park, H. S. Rugo, Binghe Xu, Filipa Cardoso, Zaha Mitri, Reshma Mahtani, K. Dunton, Y. Wang, Dhiraj Gambhire, F. Cottone, N. Harbeck, David Cameron, Shanu Modi